Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.

NCT Number	NCT06600698
Lead Sponsor	Milton S. Hershey Medical Center
Conditions	Prostate Cancer
Enrollment	45 participants
Start Date	2025-05-07
Primary Completion	2027-05-01 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-23